What is Barrington Research's Forecast for MMSI Q2 Earnings?

Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) - Barrington Research cut their Q2 2025 EPS estimates for Merit Medical Systems in a research note issued to investors on Thursday, October 31st. Barrington Research analyst M. Petusky now forecasts that the medical instruments supplier will post earnings per share of $1.05 for the quarter, down from their prior forecast of $1.06. Barrington Research currently has a "Outperform" rating and a $114.00 price objective on the stock. The consensus estimate for Merit Medical Systems' current full-year earnings is $3.36 per share. Barrington Research also issued estimates for Merit Medical Systems' Q3 2025 earnings at $0.95 EPS, Q4 2025 earnings at $0.92 EPS, FY2025 earnings at $3.80 EPS and FY2026 earnings at $4.25 EPS.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last announced its earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.80 by $0.06. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The company had revenue of $339.85 million for the quarter, compared to analyst estimates of $334.60 million. During the same quarter in the previous year, the company earned $0.75 earnings per share. The firm's quarterly revenue was up 7.8% compared to the same quarter last year.

MMSI has been the subject of several other research reports. Piper Sandler reissued an "overweight" rating and issued a $110.00 price objective (up previously from $100.00) on shares of Merit Medical Systems in a research note on Monday, September 9th. StockNews.com downgraded shares of Merit Medical Systems from a "buy" rating to a "hold" rating in a research note on Sunday. Wells Fargo & Company lifted their target price on Merit Medical Systems from $85.00 to $103.00 and gave the company an "equal weight" rating in a report on Monday, September 16th. Needham & Company LLC restated a "buy" rating and set a $109.00 price target on shares of Merit Medical Systems in a report on Thursday. Finally, Bank of America boosted their price objective on Merit Medical Systems from $92.00 to $103.00 and gave the stock a "neutral" rating in a research report on Monday, September 16th. Three investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $103.36.

Merit Medical Systems Trading Up 0.3 %

Merit Medical Systems stock traded up $0.28 during midday trading on Monday, reaching $99.08. 427,977 shares of the stock traded hands, compared to its average volume of 437,928. The firm has a market cap of $5.77 billion, a PE ratio of 48.84, a price-to-earnings-growth ratio of 2.45 and a beta of 0.89. The company has a current ratio of 5.36, a quick ratio of 4.64 and a debt-to-equity ratio of 0.57. The company has a 50-day simple moving average of $96.60 and a two-hundred day simple moving average of $88.11. Merit Medical Systems has a 12-month low of $65.46 and a 12-month high of $101.60.

Institutional Investors Weigh In On Merit Medical Systems

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Norden Group LLC acquired a new position in shares of Merit Medical Systems in the 1st quarter valued at $293,000. Sequoia Financial Advisors LLC purchased a new position in shares of Merit Medical Systems during the first quarter worth about $336,000. BNP Paribas Financial Markets increased its position in Merit Medical Systems by 55.3% in the 1st quarter. BNP Paribas Financial Markets now owns 52,953 shares of the medical instruments supplier's stock valued at $4,011,000 after acquiring an additional 18,863 shares during the period. Fidelis Capital Partners LLC purchased a new stake in Merit Medical Systems during the 1st quarter valued at approximately $90,000. Finally, FORA Capital LLC acquired a new stake in Merit Medical Systems during the 1st quarter worth approximately $577,000. 99.66% of the stock is owned by hedge funds and other institutional investors.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.